Tacrolimus (FK506): The pros and cons of its use as an immunosuppressant in pediatric liver transplantation

Clinical and Investigative Medicine

Volumn 19, Issue 5, 1996, Pages 389-392

  Cox, Kenneth L ^a   Freese, Deborah K ^b  

^a STANFORD UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; OKT 3; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG POTENCY; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEALTH CARE COST; HIRSUTISM; HOSPITALIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS;

EID: 0029845588     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46(4):746-94.
2. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-6.
3. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allogratt rejection. Lancet 1994;344:423-8.
4. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (Tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: results of the US multicenter trial. Transplantation 1995;59(4):530-6.
5. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994;220(3): 297-309.
6. Tzakis AG, Reyes J, Todo S, et al. FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991;23:3010-5.
7. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
8. Abouljoud MS, Levy MF, Klintmalm GB Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine a US Multicenter trial. US Multicenter Study Group. Transplant Proc 1995;27: 1121-3.
9. Staschak S, Wagner S, Block D, et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. Transplant Proc 1990;22(suppl 1):47-9.
10. Lin CY, Lee SF. Comparison of pharmacokinetics between CsA capsules and Sandimmune Neoral in pediatric patients. Transplant Proc 1994;26(5):2973-4.
11. Nakazato P, Cox K, Concepcion W, et al. Early experience with FK 506 induction immunosuppression - suggestion for using oral FK 506. Transplant Proc 1991;23:3019-21.
12. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-6.
13. Reyes J, Tzakis A, Green M, et al. Posttransplant Iymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc 1991; 23:3044-6.
14. Ventura HO, Lavie CJ, Messerli FH, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens 1994;8:233-7.
15. Caceiarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61:1188-92.